01.13.26 -- Customer Service As Important As Capacity And Capability

Economic volatility, regulatory uncertainty, and capacity constraints pose major risks to CDMOs, threatening growth, profitability, and long-term sustainability in an increasingly competitive global market.

Optimize your biopharmaceutical technology transfer by prioritizing clear communication, thorough training, and strategic planning to ensure success.

Discover how one family defied the odds — bringing a lifesaving gene therapy from idea to treatment in just 14 months after a devastating rare disease diagnosis.

Fragmented processes are stalling progress. By aligning CDMOs through transparency and standards, developers can move past the COGS obsession and stabilize the supply chain.

While clinical efficacy is the critical benchmark for any drug program, ensuring manufacturability is also vital. An experienced CDMO can help you establish efficient and cost-effective production strategies.

Using cells with a pre-engineered TARGATT™ landing pad, we achieve inducible expression within just 4-6 weeks after donor plasmid creation, significantly reducing development time and effort.

Fragmented supply chains increase risk and delay execution. Integration is key to establish a unified framework that enhances control, reduces administrative burden, and ensures program predictability.

Design of Experiment (DoE) methods streamline the development of robust, phase-appropriate potency and functional assays, ensuring testing that supports scalable cell therapy development.

Accelerate access to high-quality, cost-effective lentiviral vectors with our intensified TFDF-based manufacturing platform, delivering multi-fold yield improvements and space-efficient production.

Specialized cell collection services depend on access to a large, diverse donor pool as well as robust donor screening and efficient collection practices.

Learn how a science-driven and digitally structured approach reduced onboarding timelines for gene therapy from 12 months to just 3, setting a new benchmark in technology transfers.

Comprehensive global services accelerate biologics and cell therapy development, offering discovery, GMP manufacturing, and advanced platforms for efficient preclinical, clinical, and commercial stages.

Operating from state-of-the-art GMP facilities, we provide services to commercial, academic, and government clients, with innovation through GMP manufacturing, QC testing, to aseptic fill/finish.

Explore the full scope of integrated services spanning multiple advanced therapy modalities, development, and GMP manufacturing. See models support programs from concept to clinic.

Immunotherapy stimulates the immune system to fight cancer. Using human primary cells instead of immortalized lines improves relevance, reflecting in vivo conditions for better therapy development.

Whether your program requires research-grade (RG), high-quality (HQ), or GMP-grade pDNA, we provide manufacturing solutions backed by quality control, regulatory expertise, and full traceability.

See the outline of lean manufacturing strategies for cell and gene therapies, emphasizing digitization, automation, and hybrid batch records to enhance efficiency and scalability.